Nuvalent is a biotechnology company that is focused on developing small molecule kinase inhibitors for cancer treatment. The company's lead product candidate, NUV-520, is a potent and selective inhibitor of the ERK kinase pathway, which is frequently dysregulated in cancer. Nuvalent is also developing a pipeline of other kinase inhibitors for the treatment of various cancers. The company was founded in 2019 and is headquartered in Pittsburgh, Pennsylvania.